232 related articles for article (PubMed ID: 32915978)
1. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Oh ST; Talpaz M; Gerds AT; Gupta V; Verstovsek S; Mesa R; Miller CB; Rivera CE; Fleischman AG; Goel S; Heaney ML; O'Connell C; Arcasoy MO; Zhang Y; Kawashima J; Ganz T; Kowalski M; Brachmann CB
Blood Adv; 2020 Sep; 4(18):4282-4291. PubMed ID: 32915978
[TBL] [Abstract][Full Text] [Related]
2. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
3. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
Asshoff M; Petzer V; Warr MR; Haschka D; Tymoszuk P; Demetz E; Seifert M; Posch W; Nairz M; Maciejewski P; Fowles P; Burns CJ; Smith G; Wagner KU; Weiss G; Whitney JA; Theurl I
Blood; 2017 Mar; 129(13):1823-1830. PubMed ID: 28188131
[TBL] [Abstract][Full Text] [Related]
4. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
6. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
7. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
Duminuco A; Chifotides HT; Giallongo S; Giallongo C; Tibullo D; Palumbo GA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201581
[TBL] [Abstract][Full Text] [Related]
8. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Oh ST; Mesa RA; Harrison CN; Bose P; Gerds AT; Gupta V; Scott BL; Kiladjian JJ; Lucchesi A; Kong T; Buckley SA; Tyavanagimatt S; Harder BG; Roman-Torres K; Smith J; Craig AR; Mascarenhas J; Verstovsek S
Blood Adv; 2023 Oct; 7(19):5835-5842. PubMed ID: 37552106
[TBL] [Abstract][Full Text] [Related]
9. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib: First Approval.
Keam SJ
Drugs; 2023 Dec; 83(18):1709-1715. PubMed ID: 37989928
[TBL] [Abstract][Full Text] [Related]
12. Momelotinib in myelofibrosis.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2024 Apr; ():1-8. PubMed ID: 38623844
[TBL] [Abstract][Full Text] [Related]
13. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract][Full Text] [Related]
15. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
16. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
17. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Mesa RA; Kantarjian H; Tefferi A; Dueck A; Levy R; Vaddi K; Erickson-Viitanen S; Thomas DA; Cortes J; Borthakur G; Pardanani AD; Estrov Z; Verstovsek S
Cancer; 2011 Nov; 117(21):4869-4877. PubMed ID: 21480207
[TBL] [Abstract][Full Text] [Related]
19. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
Gangat N; Begna KH; Al-Kali A; Hogan W; Litzow M; Pardanani A; Tefferi A
Am J Hematol; 2023 Feb; 98(2):282-289. PubMed ID: 36349465
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
